Clinical Trial Update: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of neoadjuvant durvalumab plus docetaxel, oxaliplatin and S-1 followed by surgery, with adjuvant durvalumab plus S-1, in potentially resectable MM…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Durvalumab (durvalumab)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Asan Medical Center | Conditions: Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED